Article

Pharmacokinetic profile in late pregnancy and cord blood concentration of tipranavir and enfuvirtide.

Department of Obstetrics, Charité Universitätsmedizin Berlin, Germany.
International Journal of STD & AIDS (impact factor: 1.09). 05/2011; 22(5):294-5. DOI:10.1258/ijsa.2009.009166 pp.294-5
Source: PubMed

ABSTRACT The data on the use of tipranavir and enfuvirtide in pregnancy are very limited. We performed a pharmacokinetic profile in a pregnant woman with multidrug-resistant HIV-1 infection at 37 weeks gestation. Tipranavir levels were in the therapeutic range and the cord blood concentration at delivery was relatively high when compared with other protease inhibitors. No enfuvirtide was detected in the fetal compartment. Tipranavir and enfuvirtide were successfully used in pregnancy, but possible toxicities must be kept in mind.

0 0
 · 
0 Bookmarks
 · 
16 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

37 weeks gestation
 
enfuvirtide
 
multidrug-resistant HIV-1 infection
 
pharmacokinetic profile
 
possible toxicities
 
pregnant woman
 
therapeutic range
 
tipranavir
 
Tipranavir levels
 

K Weizsaecker